Bonomo robert a (10 resultados)

Encuadernación de tapa dura. Condición: Nuevo. Estado de la sobrecubierta: New. 1� Edición. Never read, no marks.

Condición: good. Supports Goodwill of Silicon Valley job training programs. The cover and pages are in Good condition! Any other included accessories are also in Good condition showing use. Use can include some highlighting and writing, page and cover creases as well as other types visible wear.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: As New. Unread book in perfect condition.

Condición: New.

Hardcover. Condición: Brand New. 240 pages. 8.90x6.22x0.71 inches. In Stock.

Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -For many years, physicians and the public assumed that the discovery of new antimicrobial agents would outpace the ability of bacteria to mutate and develop drug resistance. Yet the development of new antibiotics has not kept up with bacterial evolution, especially since the late 1990's. At that time a multitude of pharmaceutical companies abandoned antibiotic research because of strong economic disincentives. For example, it is challenging for these companies to recuperate the investment (typically in the hundreds of millions of dollars) made in developing a new antibiotic, which is typically prescribed for a few days, compared to drugs that treat chronic conditions like heart disease or mental illness. This situation has led the U.S. federal government to take a more active lead in addressing antibiotic resistance. Recently, the White House announced an action plan that includes improving surveillance, developing better diagnostic tools, accelerating drug development, and improving global coordination of antibiotic resistance issues. Equally important is the $1.2 billion dollars that has been pledged to fund these efforts. While we await the implementation of new policies, this issue of Infectious Disease Clinics of North America brings together leading authorities in the field of antibiotic resistance who discuss current issues including antibiotic stewardship, the changing role of the microbiology laboratory in determining antibiotic resistance in gram-negative pathogens, the continuing spread of metallo-beta-lactamases, ESBLs and KPCs, antibiotic options for treating resistant gram-negative infections such as colistin and tigecycline, resistance mechanisms and new treatment options for Mycobacterium tuberculosis, emerging resistance mechanisms in aminoglycosides, issues with antibiotic resistance in immunocompromised patients, new beta-lactamase inhibitors in the clinic, and resistance in VRE and Staphylococcus aureus. Additionally, combination therapy for resistant gram-negative infections has been advocated by some authorities and the advantages and disadvantages of this strategy will be reviewed. Englisch.…

Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Together with Consulting Editor Dr. Helen Boucher, Drs. Watkins and Bonomo have put together an issue of Infectious Disease Clinics of North America that provides the most current information on antibiotic resistance. Top experts have contributed clinical review articles that address the types of resistance based on drug class as well as emerging therapies and the future of telemedicine in the management of infections. The following topics are covered in this issue: The changing role of the clinical microbiology laboratory in defining resistance in gram-negatives; Extended-spectrum beta-lactamase-producing Enterobacteriaceae infections; Multidrug-resistant bacteria in the community; Resistance to polymyxins; Resistance in Vancomycin-resistant enterococci; Resistance to newer beta-lactamase inhibitors; Antibiotic-resistant infections in the immunocompromised host; Emerging therapies for MRSA infections; Drug-resistant tuberculosis; Aminoglycoside resistance; The role of antibiotic stewardship and telemedicine in the management of MDR infections; and Emerging issues in antifungal resistance. Readers will have the current information they need to better manage antibiotic-resistant infections in patients.…

Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - For many years, physicians and the public assumed that the discovery of new antimicrobial agents would outpace the ability of bacteria to mutate and develop drug resistance. Yet the development of new antibiotics has not kept up with bacterial evolution, especially since the late 1990's. At that time a multitude of pharmaceutical companies abandoned antibiotic research because of strong economic disincentives. For example, it is challenging for these companies to recuperate the investment (typically in the hundreds of millions of dollars) made in developing a new antibiotic, which is typically prescribed for a few days, compared to drugs that treat chronic conditions like heart disease or mental illness. This situation has led the U.S. federal government to take a more active lead in addressing antibiotic resistance. Recently, the White House announced an action plan that includes improving surveillance, developing better diagnostic tools, accelerating drug development, and improving global coordination of antibiotic resistance issues. Equally important is the $1.2 billion dollars that has been pledged to fund these efforts. While we await the implementation of new policies, this issue of Infectious Disease Clinics of North America brings together leading authorities in the field of antibiotic resistance who discuss current issues including antibiotic stewardship, the changing role of the microbiology laboratory in determining antibiotic resistance in gram-negative pathogens, the continuing spread of metallo-beta-lactamases, ESBLs and KPCs, antibiotic options for treating resistant gram-negative infections such as colistin and tigecycline, resistance mechanisms and new treatment options for Mycobacterium tuberculosis, emerging resistance mechanisms in aminoglycosides, issues with antibiotic resistance in immunocompromised patients, new beta-lactamase inhibitors in the clinic, and resistance in VRE and Staphylococcus aureus. Additionally, combination therapy for resistant gram-negative infections has been advocated by some authorities and the advantages and disadvantages of this strategy will be reviewed.…